NASDAQ: SCNIScinai Immunotherapeutics Ltd Stock
$0.36+0.03 (+9.09%)
Updated Jun 15, 2026
SCNI Price
$0.36
Fair Value Price
N/A
Market Cap
$0.00
52 Week Low
$0.30
52 Week High
$3.48
P/E
N/A
P/B
0x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.5
Operating Cash Flow
N/A
Beta
0.96
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SCNI Overview
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SCNI's potential to beat the market
- SCNI doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SCNI
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.59 | A | |
| $53.00 | A | |
| $16.00 | A |
Be the first to know about important SCNI news, forecast changes, insider trades & much more!
SCNI News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SCNI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SCNI's short-term assets ($3.61M) exceed its short-term liabilities ($2.69M)
Short-term Liabilities Financials
SCNI's short-term assets ($3.61M) exceed its long-term liabilities ($3.14M)
Long-term Liabilities Financials
SCNI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more SCNI due diligence checks available for Premium users.
Valuation
SCNI fair value
Fair Value of SCNI stock based on Discounted Cash Flow (DCF)
Price
$0.36
Fair Value
$1.67
Undervalued by
78.42%
SCNI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
16.41x
Market
14.3x
SCNI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0x
Industry
4.89x
SCNI's financial health
Profit margin
Revenue
$489.0k
Net Income
$3.6M
Profit Margin
731.5%
Assets to liabilities
Assets
$17.6M
Liabilities
$5.8M
Debt to equity
0.5
SCNI's short-term assets ($3.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SCNI's short-term assets ($3.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SCNI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SCNI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.5M
Investing
$2.7M
Financing
$11.0k
SCNI vs Biotech Stocks
Scinai Immunotherapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.